JAK1 and rheumatoid arthritis: While Tofacitinib has not been directly implicated in the regulation of MHC-II, JAK1/2 inhibitor Baricitinib, a drug approved for Rheumatoid arthritis, has been shown to modulate MHC-II on allogenic antigen-presenting cells and prevent graft vs host disease (50).